New and old treatment modalities in primary myelofibrosis

Cancer Journal

Volumn 13, Issue 6, 2007, Pages 377-383

  Cervantes, Francisco ^a,d   Mesa, Ruben ^b   Barosi, Giovanni ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b MAYO CLINIC   (United States)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d Hospital Clénic   (Spain)

Author keywords

Idiopathic myelofibrosis; Immunomodulatory drugs; Myelofibrosis with myeloid metaplasia; Primary myelofibrosis; Stem cell transplantation; Treatment; Tyrosine kinase inhibitors

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; AP 11014; BORTEZOMIB; CORTICOSTEROID; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYCLOSPORIN A; DANAZOL; FLUOXYMESTERONE; GC 1008; HYDROXYUREA; IMATINIB; LENALIDOMIDE; LESTAURTINIB; LY 580276; MELPHALAN; METANDIENONE; NANDROLONE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXYMETHOLONE; PIRFENIDONE; POMALIDOMIDE; PREDNISONE; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ERYTHROPOIETIN; SB 505124; SD 208; SEMAXANIB; TG 101209; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; ANTINEOPLASTIC AGENT;

AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANDROGEN THERAPY; ANEMIA; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLUID RETENTION; FOLLOW UP; HIRSUTISM; HUMAN; LIVER FUNCTION; LIVER TUMOR; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; MYELOID METAPLASIA; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROSTATE TUMOR; QUALITY OF LIFE; REDUCED INTENSITY CONDITIONING; REVIEW; SIDE EFFECT; SPLENECTOMY; SPLENOMEGALY; SURVIVAL; THROMBOCYTOPENIA; VIRILIZATION; ARTICLE; MIDDLE AGED; STEM CELL TRANSPLANTATION;

AGED; ANTINEOPLASTIC AGENTS; HUMANS; MIDDLE AGED; MYELOFIBROSIS; STEM CELL TRANSPLANTATION;

EID: 39749167036     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31815a7c0a     Document Type: Review

References (63)

1. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood. 1978;51:189-194.
2. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17:2954-2970.
3. Cervantes F. Modern management of myelofibrosis. Br J Haematol. 2005;128:583-592.
4. Petti MC, Latagliata R, Spadea T, et al. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2002;116: 576-581.
5. Brubaker LH, Briere J, Laszlo J, et al. Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only. Arch Intern Med. 1982;142:1533-1537.
6. Cervantes F, Alvarez-Larran A, Domingo A, et al. Efficacy and tolerability of danazol as a treatment for the anemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol. 2005;129:771-775.
7. Cervantes F, Alvarez-Larrán A, Hernández-Boluda JC, et al. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol. 2004;127:399-403.
8. Cervantes F, Alvarez-Larrán A, Hernández-Boluda JC, et al. Efficacy and safety of darbepoetin-alpha in the anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol. 2006;134:184-186.
9. Radin AI, Kim HT, Grant BW, et al. Phase II study of α interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Cancer. 2003;98:100-109.
10. Centenara E, Guarnone R, Ippoliti G, et al. Cyclosporin-A in severe refractory anemia of myelofibrosis with myeloid metaplasia: a preliminary report. Haematologica. 1998;83:622-626.
11. Tefferi A, Mesa RA, Nagomey DN, et al. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95:2226-2233.
12. Elliott MA, Chen MG, Silverstein MN, et al. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 1998;103:505-511.
13. Price F, Bell H. Spinal cord compression due to extramedullary hema- topoiesis: successful treatment in a patient with long standing myelofibrosis. JAMA. 1985;53:2876-2877.
14. Barosi G, Grossi A, Comotti B, et al. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;114:78-83.
15. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101:2534-2541.
16. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108:1158-1164.
17. Tefferi A, Lasho TL, Mesa RA, et al. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia. 2007;21:1827-1828.
18. Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141-196.
19. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-β signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004;3: 1011-1022.
20. Giles FJ, Cooper MA, Silverman L, et al. Phase II study of SU5416 - a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor - in patients with refractory myeloproliferative diseases. Cancer. 2003;97:1920-1928.
21. Wagner-Ballon O, Gastinne T, Tulliez M, et al. Proteasome inhibitor bortezomib can inhibit bone marrow fibrosis development in a murine model of myelofibrosis [abstract]. Blood. 2005;106:2582.
22. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6- methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658-6661.
23. Pardanani A, Hood J, Lasho T, et al. TG101209, a selective JAK2 kinase inhibitor, suppresses endogenous and cytokine-supported colony formation from hematopoietic progenitors carrying JAK2V617F or MPLW515K/L mutations. ASH Annual Meeting Abstr. 2006;108:2680.
24. Grandage VL, Everington T, Linch DC, et al. Go6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br J Haematol. 2006;135:303-316.
25. V617F activity and polycythemia vera cell growth. J Biol Chem. 2006;282: 3428-3432.
26. Giles F, Freedman SJ, Xiao A, et al. MK-0457, a novel multikinase inhibitor, has activity in refractory AML, including transformed JAK2 positive myeloproliferative disease (MPD), and in Philadelphia-positive ALL. Blood. 2006;108:1967.
27. Dobrzanski P, Hexner E, Serdikoff C, et al. CEP-701 is a JAK2 inhibitor which attenuates JAK2/STAT5 signaling pathway and the proliferation of primary cells from patients with myeloproliferative disorders. Blood. 2006;108:3594.
28. Giles F, List A, Carrol M, et al. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leuk Res. 2007;31:821-827.
29. 1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;114:111- 113.
30. Schlingensiepen K, Bischof, A, Egger, T, et al. The TGF-β1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: preclinical studies [abstract]. Proc Am Soc Clin Oncol. 2004;22(14 suppl):3132.
31. Sawyer JS, Beight DW, Britt KS, et al. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. Bioorg Med Chem Lett. 2004;14:3581-3584.
32. Gellibert F, Woolven J, Fouchet MH, et al. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-β type I receptor inhibitors. J Med Chem. 2004;47:4494-4506.
33. Callahan JF, Burgess JL, Fornwald JA, et al. Identification of novel inhibitors of the transforming growth factor β1 (TGF-β1) type 1 receptor (ALK5). J Med Chem. 2002;45:999-1001.
34. Uhl M, Aulwurm S, Wischhusen J, et al. SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 2004;64:7954-7961.
35. Kvasnicka HM, Thiele J. Bone marrow angiogenesis: methods of quantification and changes evolving in chronic myeloproliferative disorders. Histol Histopathol. 2004;19:1245-1260.
36. Tefferi A, Mesa RA, Gray LA, et al. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood. 2002;99:3854-3856.
37. Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101: 4714-4716.
38. Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood. 2003;101:1692-1697.
39. Mesa RA, Camoriano JK, Geyer SM, et al. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera, and post-essential thrombocythemia. Leukemia. 2007;21:1964-1970.
40. + hematopoietic progenitors from patients with idiopathic myelofibrosis [comment]. Blood. 101:5087-5088, 2003; author reply 5088-5089.
41. Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005;23:3948-3956.
42. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
43. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
44. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007; 356:459-468.
45. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood. 1999; 93:2831-2838.
46. Guardiola P, Anderson JE, Gluckman E. Myelofibrosis with myeloid metaplasia [letter]. N Engl J Med. 2000;343:659-660.
47. Daly A, Song K, Nevill T, et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant. 2003;32:35-40.
48. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102:3912-3918.
49. Ditschkowski M, Beelen DW, Trenschel R, et al. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant. 2004;34:807-813.
50. Kerbauy DM, Gooley TA, Sale GE, et al. Hematopoietic cell transplan- tation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant. 2007;13:355-365.
51. Hertenstein B, Guardiola P, Finke J, et al. Non-myeloablative (NMA) stem cell transplantation (SCT) for myeloid metaplasia with myelofibrosis (MMM): a survey from the Chronic Leukemia Working Party of the EBMT [abstract 253]. Blood. 2002;100:70a.
52. Rondelli D, Barosi G, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood. 2005;105:4115-4119.
53. Kröger N, Zabelina T, Schieder H, et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol. 2005;128:690-697.
54. Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002;99:2255-2258.
55. Hessling J, Kroger N, Werner M, et al. Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2002;119:769- 772.
56. Merup M, Lazarevic V, Nahi H, et al. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol. 2006;135:367-373.
57. Snyder DS, Palmer J, Stein AS, et al. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Biol Blood Marrow Transplant. 2006;12:1161-1168.
58. Kröger N, Badbaran A, Holler E, et al. Monitoring of the JAK2 V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood. 2007; 109:1316-1321.
59. Li Z, Deeg HJ. Pros and cons of splenectomy in patients with myelofibrosis undergoing stem cell transplantation. Leukemia. 2001;15:465- 467.
60. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with the new scoring system. Blood. 1996;88:1013-1018.
61. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102:684- 690.
62. Dingli D, Schwager SM, Mesa RA, et al. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Cancer. 2006;106:623-630.
63. Anderson JE, Tefferi A, Craig F, et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myelofibrosis. Blood. 2001;98:586-593.